Search alternatives:
"aromatic decreased" » "ratio decreased" (Expand Search)
Showing 141 - 160 results of 219 for search '(("dramatic decrease") OR ((("aromatic decreased") OR ("automatic decrease"))))', query time: 0.19s Refine Results
  1. 141
    Akr1c19 promoter analysis.

    Akr1c19 promoter analysis. by Yasutaka Miyachi (3178986)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  2. 142
    The exploration and fitting of PFS and OS curves for cCRT population in comparison with external data.

    The exploration and fitting of PFS and OS curves for cCRT population in comparison with external data. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  3. 143
    Development and islet morphology of Akr1c19 knockout mice.

    Development and islet morphology of Akr1c19 knockout mice. by Yasutaka Miyachi (3178986)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  4. 144
    Raw data.

    Raw data. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 145
    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo.

    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 146
    Best fit and the values of the parameters.

    Best fit and the values of the parameters. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 147
    Akr1c19 expression in <i>db</i>/<i>db</i> islets and localization in MIN6 cells.

    Akr1c19 expression in <i>db</i>/<i>db</i> islets and localization in MIN6 cells. by Yasutaka Miyachi (3178986)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  8. 148
    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo. DSA for cCRT population with PAP.

    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo. DSA for cCRT population with PAP. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 149
    Base-case analysis results without or with PAP.

    Base-case analysis results without or with PAP. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 150
    Results of scenario analyses for cCRT population.

    Results of scenario analyses for cCRT population. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 151
    Cost-effectiveness acceptability curves of sugemalimab vs. placebo with and without PAP.

    Cost-effectiveness acceptability curves of sugemalimab vs. placebo with and without PAP. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 152
    Validation of modeled PFS and OS data using updated GEMSTONE-301 and external data.

    Validation of modeled PFS and OS data using updated GEMSTONE-301 and external data. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 153
    Model inputs: Base case values, ranges, and distributions for sensitivity analysis.

    Model inputs: Base case values, ranges, and distributions for sensitivity analysis. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 154
    The proportion of subsequent immunotherapy and detailed treatment strategies varied with tumor histology type at progression for patients with stage III NSCLC.

    The proportion of subsequent immunotherapy and detailed treatment strategies varied with tumor histology type at progression for patients with stage III NSCLC. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 155
    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo. DSA for sCRT population with PAP.

    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo. DSA for sCRT population with PAP. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 156
    Results of scenario analyses for sCRT population.

    Results of scenario analyses for sCRT population. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 157
    The schematics of the decision tree and the Markov state transition model.

    The schematics of the decision tree and the Markov state transition model. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 158
    Whole body glucose metabolism and insulin secretion in KO mice.

    Whole body glucose metabolism and insulin secretion in KO mice. by Yasutaka Miyachi (3178986)

    Published 2021
    Subjects:
    Save to List
    Saved in:
  19. 159
    The exploration and fitting of PFS and OS curves for sCRT population in comparison with external data.

    The exploration and fitting of PFS and OS curves for sCRT population in comparison with external data. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 160
    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo.

    Tornado diagram of one-way deterministic sensitivity analysis (DSA) of sugemalimab vs. placebo. by Wei Li (7081)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: